Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
90 studies found for:    "Familial hypercholesterolemia"
Show Display Options
Rank Status Study
21 Completed
Has Results
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)
Condition: Homozygous Familial Hypercholesterolemia
Intervention: Drug: AEGR-733
22 Terminated
Has Results
A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
Conditions: Hypercholesterolemia, Familial;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: MK-0524A
23 Recruiting A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Condition: Homozygous Familial Hypercholesterolemia (HoFH)
Interventions: Drug: Rosuvastatin 20mg;   Drug: Placebo
24 Terminated Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
Conditions: Hyperlipoproteinemia Type II;   Homozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo
25 Active, not recruiting Study of Alirocumab (REGN727/ SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
Condition: Heterozygous Familial Hypercholesterolemia
Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin);   Drug: alirocumab (REGN727/ SAR236553);   Drug: placebo
26 Completed Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
Conditions: Hyperlipoproteinemia Type II;   Heterozygous Familial Hypercholesterolemia
Interventions: Drug: Anacetrapib;   Drug: Placebo for Anacetrapib
27 Completed A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)
Condition: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Drug: Anacetrapib;   Drug: Placebo for anacetrapib
28 Completed Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia
Condition: Familial Hypercholesterolemia
Intervention: Procedure: gene therapy
29 Recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Severe Familial Hypercholesterolemia
Intervention: Biological: Evolocumab (AMG145)
30 Completed Exploratory Study of Plaque Regression
Condition: Heterozygous Familial Hypercholesterolemia
Intervention: Drug: CER-001
31 Unknown  Soy Food Intervention Trial
Condition: Familial Hypercholesterolemia
Interventions: Dietary Supplement: soy protein diet;   Dietary Supplement: rapeseed oil
32 Completed Atorvastatin Three Year Pediatric Study
Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
33 Completed
Has Results
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
Condition: Familial Hypercholesterolemia
Interventions: Drug: Rosuvastatin;   Drug: Placebo
34 Completed Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Condition: Homozygous Familial Hypercholesterolemia
Interventions: Biological: Evolocumab (AMG145);   Other: Placebo
35 Completed
Has Results
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
Conditions: Heterozygous Familial Hypercholesterolemia;   Coronary Artery Disease
Interventions: Drug: mipomersen sodium;   Drug: placebo
36 Terminated Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Condition: Heterozygous Familial Hypercholesterolaemia
Interventions: Drug: Placebo;   Drug: Eprotirome
37 Completed Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Condition: Type II Hyperlipidaemia
Interventions: Drug: Placebo;   Drug: JTT-705 300mg;   Drug: JTT-705 600mg;   Drug: JTT-705 900mg
38 Completed Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
Condition: Type II Hyperlipidemia
Interventions: Drug: JTT-705 600 mg and pravastatin 40 mg;   Drug: JTT-705 300 mg and pravastatin 40 mg;   Drug: Placebo and pravastatin 40 mg
39 Unknown  Effect of Rapeseed Oil and Sunflower Oil
Condition: Familial Hypercholesterolemia
Interventions: Dietary Supplement: rapeseed oil;   Dietary Supplement: sunflower oil
40 Not yet recruiting Effect of Omega-3 Fatty Acid on Endothelial Function
Condition: Familial Hypercholesterolemia
Interventions: Drug: Omega-3;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years